Turn Therapeutics (NASDAQ:TTRX) Cut to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Turn Therapeutics from “hold” to “sell,” though analyst sentiment remains mixed. The stock has an overall “Moderate Buy” rating and an average price target of $9.00.
• Turn Therapeutics shares opened at $10.57, with a market capitalization of approximately $314.9 million and a 12-month trading range of $2.57 to $16.45. The company reported a quarterly loss of $0.20 per share and analysts expect a full-year loss of $0.40 per share.
• Several institutional investors recently initiated or increased positions in TTRX, including Bank of America, Jefferies Financial Group, Bridgewater Advisors, and DDFG.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Sunday, Wall Street Zen reports.

Several other analysts have also recently weighed in on the stock. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a "strong-buy" rating in a research note on Monday, July 20th. Lucid Cap Mkts raised Turn Therapeutics to a "strong-buy" rating in a research report on Thursday, September 24th. WBB Securities reiterated a "sell" rating and issued a $10.00 price target on shares of Turn Therapeutics in a research report on Monday, September 14th. Weiss Ratings cut Turn Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 18th. Finally, Zacks Research raised Turn Therapeutics to a "hold" rating in a research note on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $9.00.

Turn Therapeutics Stock Performance

Shares of TTRX stock opened at $10.57 on Friday. The company's fifty day simple moving average is $11.60 and its 200-day simple moving average is $7.90. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83. Turn Therapeutics has a 12 month low of $2.57 and a 12 month high of $16.45. The firm has a market cap of $314.88 million and a PE ratio of -36.45.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. Equities research analysts expect that Turn Therapeutics will post -0.40 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of TTRX. TD Waterhouse Canada Inc. acquired a new stake in Turn Therapeutics in the third quarter worth $40,000. Bank of America Corp DE acquired a new position in shares of Turn Therapeutics during the second quarter valued at about $103,000. Jefferies Financial Group Inc. acquired a new position in shares of Turn Therapeutics during the second quarter valued at about $119,000. DDFG Inc raised its holdings in shares of Turn Therapeutics by 34.9% during the first quarter. DDFG Inc now owns 70,534 shares of the company's stock valued at $226,000 after purchasing an additional 18,246 shares during the period. Finally, Bridgewater Advisors Inc. bought a new position in shares of Turn Therapeutics during the 2nd quarter worth about $242,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.